Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis.
Boz C, Terzi M, Özer B, Turkoglu R, Karabudak R, Efendi H, Soysal A, Sevim S, Altintas A, Kurne A, Akçalı A, Akman G, Yüceyar N, Balcı BP, Ekmekci Ö, Karahan SZ, Demirkıran M, Altunrende B, Turan ÖF, Gökçen GözübatıkÇelik, Kale N, Köseoğlu M, Ozakbas S. Boz C, et al. Among authors: efendi h. Mult Scler Relat Disord. 2019 Nov;36:101376. doi: 10.1016/j.msard.2019.101376. Epub 2019 Aug 26. Mult Scler Relat Disord. 2019. PMID: 31473488
A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients - FINE Trial.
Demır GA, Türkoğlu R, Saıp S, Yüceyar N, Efendı H, Turan ÖF, Ağan K, Terzı M, Boz C, Tuncer A, Koçer B, Kasap M, Çalişkan Z; Fine Study Group. Demır GA, et al. Among authors: efendi h. Noro Psikiyatr Ars. 2017 Jun 22;56(4):253-257. doi: 10.5152/npa.2017.20515. eCollection 2019 Dec. Noro Psikiyatr Ars. 2017. PMID: 31903032 Free PMC article.
Differences Between General Neurologists and Multiple Sclerosis Specialists in the Management of Multiple Sclerosis Patients: A National Survey.
Kürtüncü M, Tuncer A, Uygunoğlu U, Çalişkan Z, Paksoy AK, Efendı H, Kocaman AS, Özcan C, Terzı M, Turan ÖF, Saıp S, Karabudak R, Sıva A. Kürtüncü M, et al. Among authors: efendi h. Noro Psikiyatr Ars. 2017 Jun 20;56(4):269-272. doi: 10.5152/npa.2017.19387. eCollection 2019 Dec. Noro Psikiyatr Ars. 2017. PMID: 31903035 Free PMC article.
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?
Sen S, Karabudak R, Schiavetti I, Demir S, Ozakbas S, Tutuncu M, Petek Balci B, Turan OF, Uzunkopru C, Koseoglu M, Yetkin MF, Gunduz T, Gumus H, Kale Icen N, Carmisciano L, Terzi M, Acar P, Gungor Dogan I, Baba C, Tuncer A, Uygunoglu U, Sormani MP, Efendi H, Siva A; Turkish MS Study Group. Sen S, et al. Among authors: efendi h. Mult Scler Relat Disord. 2021 Jul;52:102968. doi: 10.1016/j.msard.2021.102968. Epub 2021 Apr 18. Mult Scler Relat Disord. 2021. PMID: 33940495 Free PMC article.
The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?
Sen S, Tuncer A, Ozakbas S, Uzunkopru C, Baba C, Demir S, Beckmann Y, Gumus H, Arslan G, Kilic AK, Altintas A, Yuceyar N, Turan OF, Tutuncu M, Terzi M, Acar P, Bunul SD, Balci BP, Bir LS, Koseoglu M, Mungan S, Gunduz T, Dogan IG, Kotan D, Uygunoglu U, Ekmekci O, Demirkiran M, Kamisli O, Kabay SC, Tamam Y, Omerhoca S, Sevim S, Guler S, Kurtuncu M, Efendi H, Karabudak R, Siva A. Sen S, et al. Among authors: efendi h. Mult Scler Relat Disord. 2022 Feb;58:103399. doi: 10.1016/j.msard.2021.103399. Epub 2021 Nov 19. Mult Scler Relat Disord. 2022. PMID: 35216782 Free PMC article.
A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis.
Ponzano M, Schiavetti I, Bovis F, Landi D, Carmisciano L, De Rossi N, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Bragadin MM, Cocco E, Scandellari C, Cavalla P, Pesci I, Confalonieri P, Perini P, Bergamaschi R, Inglese M, Petracca M, Trojano M, Tedeschi G, Comi G, Battaglia MA, Patti F, Fragoso YD, Sen S, Siva A, Karabudak R, Efendi H, Furlan R, Salvetti M, Sormani MP. Ponzano M, et al. Among authors: efendi h. Mult Scler Relat Disord. 2022 Jul;63:103909. doi: 10.1016/j.msard.2022.103909. Epub 2022 May 25. Mult Scler Relat Disord. 2022. PMID: 35675744 Free PMC article.
The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis.
Boz C, Ozakbas S, Terzi M, Karabudak R, Sevim S, Turkoglu R, Soysal A, Balcı BP, Efendi H, Turan ÖF, Yüceyar N, Yetkin MF, Karahan SZ, Demirkıran M, Guler S, Agan K, Kıylıoğlu N, Baba C, Tuncer A, Köseoğlu M. Boz C, et al. Among authors: efendi h. Neurol Sci. 2023 Jun;44(6):2121-2129. doi: 10.1007/s10072-023-06608-z. Epub 2023 Jan 23. Neurol Sci. 2023. PMID: 36689010
68 results